Erratum: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper (Osteoporos Int, (2012) 23, 11, (2567-2576), 10.1007/s00198-011-1870-0);Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: An ESCEO position paper

Osteoporosis International

Volumn 23, Issue 11, 2012, Pages 2567-2576

  Rizzoli, R ^a   Body, J J ^b   De Censi, A ^c,d   Reginster, J Y ^e   Piscitelli, P ^f   Brandi, M L ^f  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c GALLIERA HOSPITAL   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Aromatase inhibitors; Bisphosphonates; Bone loss; Breast cancer; Fracture risk

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; LETROZOLE; PARATHYROID HORMONE; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BODY MASS; BONE ATROPHY; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER MORTALITY; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; DISEASE FREE SURVIVAL; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FRACTURE; HIGH RISK PATIENT; HUMAN; JAW OSTEONECROSIS; LUMBAR SPINE; MEDICAL EXPERT; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PARATHYROID HORMONE BLOOD LEVEL; POST TREATMENT SURVIVAL; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84868193373     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1930-0     Document Type: Erratum

References (95)

1. Howlader N, Noone AM, Krapcho M et al (2011) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site 2011.
2. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
3. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747
4. Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518
5. Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. JNCI 98:1285-1291
6. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141
7. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559-570
8. Thürlimann B, Keshaviah A, Coates AS (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Engl J Med 353:2747-2757
9. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 97:1262-1271
10. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442
11. McCloskey E (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044-1051
12. Mouridsen HT, Robert NJ (2005) The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 41:1678-1689
13. Perez EA (2007) Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18:26-35
14. Body JJ, Bergmann P, Boonen S et al (2007) Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 18:1439-1450
15. Burstein HJ, Prestrud AA, Seidenfeld J (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796
16. Coates AS, Keshaviah A, Thürlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
17. Lonning P (2006) Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 16:518-520
18. Kanis JA, Melton LJ, Christiansen C 3rd et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141
19. Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223
20. Gnant M, Mlineritsch B, Luschin-Ebengreuth G (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849
21. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
22. Chen Z, Maricic M, Pettinger M et al (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 104:1520-1530
23. Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051-1057
24. Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119-127
25. Szabo KA, Webber CE, Adachi JD et al (2011) Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study. Bone 48:218-224
26. Tang SC (2010) Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Oncology 79:13-26
27. Ghazi M, Roux C (2009) Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. Best Pract Res Clin Rheumatol 23:805-811
28. Lønning PE, Geisler J, Krag LE (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137
29. Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84
30. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
31. Delmas PD, Ensrud KE, Adachi JD et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
32. Freedman AN, Yu B, Gail MH et al (2011) Benefit/Risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29:2327-2333
33. Hadji P, Ziller M, Albert US et al (2010) Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. Br J Cancer 102:645-650
34. Kanis JA, McCloskey EV, Powles T et al (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181
35. Edwards SA, Chiarelli AM, Ritvo P et al (2011) Satisfaction with initial screen and compliance with biennial breast screening at centers with and without nurses. Cancer Nurs 34:293-301
36. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
37. Ensrud KE, Black DM, Palermo L et al (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157:2617-2624
38. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
39. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
40. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
41. Eastell R, Adams J, Clack G et al (2011) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 22:857-862
42. Joerger M, Thürlimann B (2009) Update of the BIG 1-98 Trial: where do we stand? Breast 18:S78-S82
43. Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20:1489-1498
44. Coombes RC, Hall E, Gibson LJ (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 350:1081-1092
45. Goss PE, Strasser-Weippl K (2004) Prevention strategies with aromatase inhibitors. Clin Cancer Res 10:372S-379S
46. Coleman RE, Banks LM, Girgis SI (2010) Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 124:153-161
47. Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24:5305-5312
48. Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
49. Cummings SR, Duong T, Kenyon E et al (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220
50. Prentice AM (2008) Vitamin D deficiency: a global perspective. Nutr Rev 66:S153-S164
51. Mithal A, Wahl DA, Bonjour JP et al (2009) Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 20:1807-1820
52. Bertoldo F, Pancheri S, Zenari S et al (2010) Emerging drugs for the management of cancer treatment induced bone loss. Expert Opin Emerg Drugs 15:323-342
53. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B et al (2010) Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 21:1121-1132
54. Peterlik M, Grant WB, Cross HS et al (2007) Calcium, vitamin D and cancer. Anticancer Res 29:3687-3698
55. Holick MF (2007) Vitamin D deficiency. N EnglJ Med 357:266-281
56. Adami S, Giannini S, Bianchi G et al (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20:239-244
57. Bischoff-Ferrari HA, Willett WC, Wong JB (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 169:551-561
58. Chen P, Hu P, Xie D et al (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 121:469-477
59. Lazzeroni M, Gandini S, Puntoni M et al (2011) The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. Breast 20(Suppl 3):S36-41
60. Garland CF, Comstock GW, Garland FC et al (1989) Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2:1176-1178
61. Tuohimaa P, Tenkanen L, Ahonen M et al (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108:104-108
62. Servitja S, Nogués X, Prieto-Alhambra D et al, Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast. 2011 Sep 15. [Epub ahead of print]
63. Prieto-Alhambra D, Javaid MK, Servitja S et al (2011 Feb) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125 (3):869-878
64. Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. [Epub ahead of print].
65. Brufsky A, Bossermann L, Caradonna R et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36 months follow-up results. Clin Breast Cancer 9(2):77-85
66. Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women receiving adjuvant letrozole: the ZO-FAST study results. Cancer 112:1001-1010
67. Eidtmann H, de Boer R, Bundred N (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194
68. De Boer R, Eidtmann H, Lluch A et al (2007) The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat 106:S501
69. Brufsky A, Bundred N, Coleman R et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514
70. De Boer RH, Bundred N, Eidtmann H et al (2010) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Poster presented at: the 2010 San Antonio Breast Cancer Symposium; December 11, 2010; San Antonio, Texas
71. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820-828
72. Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641
73. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy. Lancet Oncol 9:840-849
74. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
75. Coleman RE, Marshall M et al (2011) Breast Cancer Adjuvant Therapy with Zoledronic Acid. N Engl J Med 365(15):1396-1405
76. Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342
77. Eastell R, Van Poznak CH, Hannon RA et al (2007) The SABRE study (Study of Anastrozole with the Bisphosphonate RisedronatE): 12 month analysis. J Bone Miner Res 22:S113
78. Hines SL, Mincey BA, Sloan JA (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27(7):1047-1053, Epub 2008 Dec 15
79. Saarto T, Bloqvist C, Valimaki M et al (1997) Clodronate improbe bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogen. Br Cancer 75:602-605
80. Paterson AHG (2006) The role of bisphosphonates in early breast cancer. Oncologist 11:S13-S19
81. Van den Wyngaert T, Huizing MT, Fossion E et al (2009) Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 14:181-191
82. Ellis GK, Bone HG, Chlebowski R et al (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118:81-87
83. Hillner B, Ingle J, Berenson J et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer. J Clin Oncol 21:4042-4057
84. Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407-1416
85. Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. [Epub ahead of print]
86. Body JJ, Bergmann P, Boonen S et al (2007) Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian bone club. Osteoporos Int 18:1439-1450
87. Reid DM, Doughty J, Eastell R et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34:S3-S18
88. Kanis JA, Johnell O, Oden A et al (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
89. Donaldson MG, Palermo L, Schousboe JT et al (2009) FRAX and risk of vertebral fractures: the fracture intervention trial. J Bone Miner Res 24:1793-1799
90. Body JJ (2011) New developments for treatment and prevention of bone metastases. Curr Opin Oncol 23:338-342
91. Singh S, Cuzick J, Edwards R et al. Effect of anastrozole on bone mineral density after one year of treatment. Results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Breast Cancer Res Treat 2007; 106(Suppl 1: S9 Abstr 28).
92. Confavreux CB, Fontana A, Guastalla JP et al., Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates, Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.
93. Greenspan SL, Brufsky A, Lembersky BC (2008) Risedronate prevents bone loss in breast cancer, survivors: a 2-year, randomized, double-blind, placebocontrolled clinical trial. J Clin Oncol 26 (16):2644-2652, Epub 2008 Apr 21
94. Markopoulos C, Tzoracoleftherakis E, Polychronis A et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12((2):R24, Epub 2010 Apr 16
95. Van Poznak C, Hannon RA, Mackey JR (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28(6):967-975